摘要
目的替罗非班序贯治疗在AIS静脉溶栓的临床观察。方法按照随机数字表法将本院2023年7月-2024年1月期间收治的96例AIS患者分为2组,每组各48例。rt-PA组给予阿替普酶静脉溶栓,序贯组在rt-PA组的基础上联合替罗非班序贯疗法。治疗14d后,观察2组患者临床疗效、炎症因子水平、以及不良反应发生率。结果序贯组总有效率高于rt-PA组,差异有统计学意义(P<0.05);序贯组和rt-PA组IL-6、IL-10、TNF-α以及CRP表达水平均较入院时下降且序贯组低于rt-PA组,差异有统计学意义(P<0.05);2组不良反应对比差异无统计学意义(P>0.05)。结论相比较与单一rt-PA治疗AIS患者,在rt-PA的基础上联合替罗非班序贯疗法能提高治疗有效率,减轻炎症因子水平,加快病情恢复,且不会增加出血等不良反应发生的风险。
Objective To observe the clinical efficacy of sequential treatment with tirofiban in AIS intravenous thrombolysis.Methods According to the random number table method,96 AIS patients admitted to our hospital from July 2023 to January 2024 were divided into two groups,with 48 cases in each group.The rt-PA group received intravenous thrombolysis with alteplase,while the sequential group was combined with tirofiban sequential treatment on the base of the rt-PA group.After 14 days of treatment,the clinical efficacy,levels of inflammatory factors,and incidence of adverse reactions were observed in both groups of patients.Results The total effective rate of the sequential group was higher than that of the rt-PA group,and the difference was statistically significant(P<0.05).The expression levels of IL-6,IL-10,TNF-α,and CRP in the sequential group and rt PA group decreased compared with those at admission,and those in the sequential group was lower than those in the rt-PA group,with statistical significant differences(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusions Compared with the single RT-PA treatment for AIS patients,the combined sequential therapy of tirofiban on the basis of the rt-PA can improve the treatment effective rate,reduce the level of inflammatory factors,accelerate the recovery of the disease,and does not increase the risk of adverse reactions such as bleeding.
作者
高成恩
贾永林
韩新生
张保华
GAO Cheng'en;JIA Yonglin;HAN Xinsheng;ZHANG Baohua(Department of Neurology,Kaifeng Central Hospital,Kaifeng Henan 475000,China)
出处
《云南医药》
2026年第1期35-38,共4页
Medicine and Pharmacy of Yunnan
基金
河南省医学科技攻关计划项目(LHGJ20240715)。
